

**Integrin  $\alpha$ V (D2N5H) Rabbit mAb**

**Orders:** 877-616-CELL (2355)  
orders@cellsignal.com

**Support:** 877-678-TECH (8324)

**Web:** info@cellsignal.com  
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

**For Research Use Only. Not for Use in Diagnostic Procedures.**

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H M R Mk	Endogenous	135, 140	Rabbit IgG	#P06756	3685

**Product Usage Information****Application**

Western Blotting

**Dilution**

1:1000

**Specificity/Sensitivity**

Integrin  $\alpha$ V (D2N5H) Rabbit mAb recognizes endogenous levels of total Integrin  $\alpha$ V.

**Source / Purification**

Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the central region of human integrin  $\alpha$ V protein.

**Background**

Integrins are  $\alpha/\beta$  heterodimeric cell surface receptors that play a pivotal role in cell adhesion and migration, as well as in growth and survival (1,2). The integrin family contains at least 18  $\alpha$  and 8  $\beta$  subunits that form 24 known integrins with distinct tissue distribution and overlapping ligand specificities (3). Integrins not only transmit signals to cells in response to the extracellular environment (outside-in signaling), but also sense intracellular cues to alter their interaction with the extracellular environment (inside-out signaling) (1,2).

Several  $\alpha$ V subfamily members, including  $\alpha$ V $\beta$ 3,  $\alpha$ V $\beta$ 5,  $\alpha$ V $\beta$ 1, are highly expressed in active endothelial cells and cancer cells (3-6) where they play a critical role in angiogenesis and tumor metastasis (7-9). Therefore, interest has focused on  $\alpha$ V integrin as a key therapeutic target in the treatment of cancer (10-12).

**Background References**

- Liu, S. et al. (2000) *J Cell Sci* 113 ( Pt 20), 3563-71.
- Hood, J.D. and Cheresh, D.A. (2002) *Nat Rev Cancer* 2, 91-100.
- Koistinen, P. et al. (2004) *Int J Cancer* 112, 61-70.
- Davidson, B. et al. (2003) *Gynecol Oncol* 90, 248-57.
- Schwartz, E.A. et al. (1999) *Circ Res* 84, 315-22.
- Suzuma, K. et al. (1998) *Invest Ophthalmol Vis Sci* 39, 1028-35.
- Eliceiri, B.P. and Cheresh, D.A. (1999) *J Clin Invest* 103, 1227-30.
- Friedlander, M. et al. (1995) *Science* 270, 1500-2.
- Perruzzi, C.A. et al. (2003) *J Invest Dermatol* 120, 1100-9.
- Strieth, S. et al. (2006) *Int J Cancer* 119, 423-31.
- Kumar, C.C. (2003) *Curr Drug Targets* 4, 123-31.
- Tucker, G.C. (2006) *Curr Oncol Rep* 8, 96-103.

**Species Reactivity**

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

**Western Blot Buffer**

**IMPORTANT:** For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

**Applications Key**

**W:** Western Blotting

**Cross-Reactivity Key**

**H:** Human **M:** Mouse **R:** Rat **Mk:** Monkey

**Trademarks and Patents**

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

XP is a registered trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit [cellsignal.com/trademarks](http://cellsignal.com/trademarks) for more information.

**Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no

force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.